Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
7 Aug 24
8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
7 Aug 24
8-K
Regulation FD Disclosure
26 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 24
424B5
Prospectus supplement for primary offering
6 May 24
10-Q
2024 Q1
Quarterly report
6 May 24
8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
6 May 24
EFFECT
Notice of effectiveness
6 May 24
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
S-3
Shelf registration
28 Feb 24
S-8
Registration of securities for employees
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
28 Feb 24
8-K
Departure of Directors or Certain Officers
20 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
7 Nov 23
8-K
Regulation FD Disclosure
11 Sep 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
21 Jun 23
8-K
Departure of Directors or Certain Officers
6 Jun 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
4 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
S-8
Registration of securities for employees
28 Feb 23
8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
28 Feb 23
10-K
2022 FY
Annual report
28 Feb 23
8-K
Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer
16 Dec 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results
8 Nov 22
8-K
Termination of a Material Definitive Agreement
24 Oct 22
8-K
Regulation FD Disclosure
6 Oct 22
S-3ASR
Automatic shelf registration
4 Aug 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights
4 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
13 Jun 22
Latest ownership filings
4
ROBERT NELSEN
17 Jun 24
4
Hans Edgar Bishop
17 Jun 24
4
Richard Klausner
17 Jun 24
4
WILLIAM JL RIEFLIN
17 Jun 24
4
ELIZABETH G NABEL
17 Jun 24
4
OTIS W BRAWLEY
17 Jun 24
4
CATHY FRIEDMAN
17 Jun 24
SC 13G/A
ARCH Venture Fund IX, L.P.
14 Feb 24
4
Matthew Lang
13 Feb 24
4
Stephen J. Hill
13 Feb 24
4
Gary K. Lee
13 Feb 24
4
Charles W. Newton
13 Feb 24
4
Lynn Seely
13 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G
BlackRock Inc.
29 Jan 24
4
Charles W. Newton
20 Nov 23
4
Gary K. Lee
20 Nov 23
4
Lynn Seely
20 Nov 23
4
Stephen J. Hill
20 Nov 23
4
Richard Klausner
8 Sep 23
4
WILLIAM JL RIEFLIN
8 Sep 23
4
CATHY FRIEDMAN
8 Sep 23
4
ROBERT NELSEN
8 Sep 23
4
ELIZABETH G NABEL
8 Sep 23
4
OTIS W BRAWLEY
8 Sep 23
4
Hans Edgar Bishop
8 Sep 23
4
Richard Klausner
17 Aug 23
144
Notice of proposed sale of securities
15 Aug 23
144
Notice of proposed sale of securities
15 Aug 23
144
Notice of proposed sale of securities
15 Aug 23
144
Notice of proposed sale of securities
15 Aug 23
4
Matthew Lang
11 Aug 23
3
Matthew Lang
20 Jul 23
144
Notice of proposed sale of securities
17 Jul 23
144
Notice of proposed sale of securities
17 Jul 23
144
Notice of proposed sale of securities
17 Jul 23
144
Notice of proposed sale of securities
17 Jul 23
4
WILLIAM JL RIEFLIN
20 Jun 23
4
ROBERT NELSEN
20 Jun 23
4
ELIZABETH G NABEL
20 Jun 23